M&T Bank Corp Immuno Gen, Inc. Transaction History

M&T Bank Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 06, 2021	SELL	$6.5 - $10.53 $72,260 - $117,062	-11,117 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$3.7 - $7.66 $107 - $222	-29 Reduced 0.26%	11,117 $72,000
Q3 2020 Nov 06, 2020	SELL	$3.45 - $4.89 $182 - $259	-53 Reduced 0.47%	11,146 $40,000
Q2 2020 Jul 29, 2020	BUY	$3.32 - $5.34 $37,180 - $59,802	11,199 New	11,199 $52,000
Q1 2020 May 14, 2020	SELL	$2.12 - $6.8 $32,158 - $103,149	-15,169 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$2.25 - $5.8 $1,732 - $4,466	770 Added 5.35%	15,169 $77,000
Q3 2019 Nov 12, 2019	SELL	$2.22 - $3.39 $57,011 - $87,058	-25,681 Reduced 64.07%	14,399 $35,000
Q2 2019 Aug 12, 2019	BUY	$1.8 - $3.3 $8,368 - $15,341	4,649 Added 13.12%	40,080 $87,000
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $85,388 - $209,397	35,431 New	35,431 $96,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

Stay updated on M&T Bank Corp with notifications on news.